Cargando…

Potential blood-based markers of celiac disease

BACKGROUND: Blood-based diagnostics has the potential to simplify the process of diagnosing celiac disease (CD). Although high levels of autoantibodies against tissue transglutaminase (anti-TG2) are strongly indicative of active CD, several other scenarios involve a need for additional blood-based C...

Descripción completa

Detalles Bibliográficos
Autores principales: Bragde, Hanna, Jansson, Ulf, Fredrikson, Mats, Grodzinsky, Ewa, Söderman, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287385/
https://www.ncbi.nlm.nih.gov/pubmed/25298177
http://dx.doi.org/10.1186/1471-230X-14-176
_version_ 1782351779780886528
author Bragde, Hanna
Jansson, Ulf
Fredrikson, Mats
Grodzinsky, Ewa
Söderman, Jan
author_facet Bragde, Hanna
Jansson, Ulf
Fredrikson, Mats
Grodzinsky, Ewa
Söderman, Jan
author_sort Bragde, Hanna
collection PubMed
description BACKGROUND: Blood-based diagnostics has the potential to simplify the process of diagnosing celiac disease (CD). Although high levels of autoantibodies against tissue transglutaminase (anti-TG2) are strongly indicative of active CD, several other scenarios involve a need for additional blood-based CD markers. METHODS: We investigated the levels of messenger RNA (mRNA) in whole blood (n = 49) and protein in plasma (n = 22) from cases with active CD (n = 20), with confirmed CD and normalized histology (n = 15), and without a CD diagnosis (n = 14). Group differences were analyzed using Kruskal-Wallis one-way analysis of variance by ranks. We also investigated correlations between levels of potential markers, histopathology according to the modified Marsh scale, and CD risk gradient based on HLA type, using Spearman rank correlation. The relation between HLA-DQ2 gene dose effect and the expression levels of selected blood-based markers was investigated using the Mann–Whitney U test. Finally, the diagnostic performance of anti-TG2, potential blood-based CD markers, and logistic regression models of combined markers was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS: CXCL11 protein levels and TNFRSF9 and TNFSF13B mRNA levels were identified as potential CD markers. These are all affected by or involved in the regulation of the NF-κB complex. CXCL11 protein levels and IL21 and IL15 mRNA levels were correlated with histopathology according to the modified Marsh scale, as were the established CD markers. HLA genotype risk and HLA-DQ2 gene dose effect did not show any significant relations with either the potential CD markers or the established CD markers. ROC curve analysis revealed a slight, non-significant increase in the area under the curve for the combined use of anti-TG2 and different constellations of potential blood-based CD markers compared to anti-TG2 alone. CONCLUSIONS: The CD markers identified in this study further emphasize the significance of components related to NF-κB regulation in relation to CD. However, the relevance of CXCL11, TNFSF13B, TNFRSF9, and other NF-κB interacting proteins recognized by pathway analysis, needs to be further investigated in relation to diagnosis and monitoring of CD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-230X-14-176) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4287385
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42873852015-01-09 Potential blood-based markers of celiac disease Bragde, Hanna Jansson, Ulf Fredrikson, Mats Grodzinsky, Ewa Söderman, Jan BMC Gastroenterol Research Article BACKGROUND: Blood-based diagnostics has the potential to simplify the process of diagnosing celiac disease (CD). Although high levels of autoantibodies against tissue transglutaminase (anti-TG2) are strongly indicative of active CD, several other scenarios involve a need for additional blood-based CD markers. METHODS: We investigated the levels of messenger RNA (mRNA) in whole blood (n = 49) and protein in plasma (n = 22) from cases with active CD (n = 20), with confirmed CD and normalized histology (n = 15), and without a CD diagnosis (n = 14). Group differences were analyzed using Kruskal-Wallis one-way analysis of variance by ranks. We also investigated correlations between levels of potential markers, histopathology according to the modified Marsh scale, and CD risk gradient based on HLA type, using Spearman rank correlation. The relation between HLA-DQ2 gene dose effect and the expression levels of selected blood-based markers was investigated using the Mann–Whitney U test. Finally, the diagnostic performance of anti-TG2, potential blood-based CD markers, and logistic regression models of combined markers was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS: CXCL11 protein levels and TNFRSF9 and TNFSF13B mRNA levels were identified as potential CD markers. These are all affected by or involved in the regulation of the NF-κB complex. CXCL11 protein levels and IL21 and IL15 mRNA levels were correlated with histopathology according to the modified Marsh scale, as were the established CD markers. HLA genotype risk and HLA-DQ2 gene dose effect did not show any significant relations with either the potential CD markers or the established CD markers. ROC curve analysis revealed a slight, non-significant increase in the area under the curve for the combined use of anti-TG2 and different constellations of potential blood-based CD markers compared to anti-TG2 alone. CONCLUSIONS: The CD markers identified in this study further emphasize the significance of components related to NF-κB regulation in relation to CD. However, the relevance of CXCL11, TNFSF13B, TNFRSF9, and other NF-κB interacting proteins recognized by pathway analysis, needs to be further investigated in relation to diagnosis and monitoring of CD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-230X-14-176) contains supplementary material, which is available to authorized users. BioMed Central 2014-10-09 /pmc/articles/PMC4287385/ /pubmed/25298177 http://dx.doi.org/10.1186/1471-230X-14-176 Text en © Bragde et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bragde, Hanna
Jansson, Ulf
Fredrikson, Mats
Grodzinsky, Ewa
Söderman, Jan
Potential blood-based markers of celiac disease
title Potential blood-based markers of celiac disease
title_full Potential blood-based markers of celiac disease
title_fullStr Potential blood-based markers of celiac disease
title_full_unstemmed Potential blood-based markers of celiac disease
title_short Potential blood-based markers of celiac disease
title_sort potential blood-based markers of celiac disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287385/
https://www.ncbi.nlm.nih.gov/pubmed/25298177
http://dx.doi.org/10.1186/1471-230X-14-176
work_keys_str_mv AT bragdehanna potentialbloodbasedmarkersofceliacdisease
AT janssonulf potentialbloodbasedmarkersofceliacdisease
AT fredriksonmats potentialbloodbasedmarkersofceliacdisease
AT grodzinskyewa potentialbloodbasedmarkersofceliacdisease
AT sodermanjan potentialbloodbasedmarkersofceliacdisease